The anti-protozoal drug pentamidine blocks K IR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel: Research paper

British Journal of Pharmacology

Volumn 159, Issue 7, 2010, Pages 1532-1541

  De Boer, Tp ^a   Nalos, L ^a   Stary, A ^b   Kok, B ^a   Houtman, Mjc ^a   Antoons, G ^a   Van Veen, Tab ^a   Beekman, Jdm ^a   De Groot, Bl ^b   Opthof, T ^a   Rook, Mb ^a   Vos, Ma ^a   Van Der Heyden, Mag ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Arrhythmia; ECG; I K1; Inward rectifier current; K IR2.1; Molecular modelling; Pentamidine

Indexed keywords

ALANINE; CHLOROQUINE; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.X; PENTAMIDINE ISETHIONATE; SPERMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOPLASM; DOG; DRUG PROTEIN BINDING; GENE MUTATION; HEART CELL CULTURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; MOLECULAR MODEL; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL;

ANIMALS; ANTIPROTOZOAL AGENTS; BLOTTING, WESTERN; CELL LINE; CYTOPLASM; DOGS; HUMANS; MUTATION; PATCH-CLAMP TECHNIQUES; PENTAMIDINE; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 77949780932     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00658.x     Document Type: Article

References (54)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Bibler MR, Chou TC, Toltzis RJ, Wade PA (1988). Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 94:1303 1306.
3. Bray PG, Barrett MP, Ward SA, De Koning HP (2003). Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 19:232 239.
4. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW et al. (2005). Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145:15 23.
5. Croft SL, Sundar S, Fairlamb AH (2006). Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111 126.
6. De Boer TP, Van der Heyden MAG, Rook MB, Wilders R, Broekstra R, Kok B et al. (2006a). Pro-arrhythmogenic potential of immature cardiomyocytes is triggered by low coupling and cluster size. Cardiovasc Res 71:704 714.
7. IR2.1 expressing cells. Med Biol Eng Comput 44:537 542.
8. K1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm 2:316 324.
9. Donnelly H, Bernard EM, Rothkotter H, Gold JWM, Armstrong D (1988). Distribution of pentamidine in patients with AIDS. J Infect Dis 157:985 989.
10. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K et al. (2008). Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 14:1013 1018.
11. Ehrlich JR (2008). Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol 52:129 135.
12. Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr., Wortham DC (1994). Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105:389 394.
13. IR2.1 channels responsible for variant 3 short QT syndrome. J Mol Cell Cardiol 47:743 747.
14. IR2.1. J Gen Physiol 127:401 419.
15. Girgis I, Gualberti J, Langan L, Malek S, Mustaciuolo V, Costantino T et al. (1997). A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 112:646 653.
16. Goa KL, Campoli-Richards DM (1987). Pentamidine isethionate: a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33:242 258.
17. Gonzalez A, Sager PT, Akil B, Rahimtoola SH, Bhandari AK (1991). Pentamidine-induced torsade de pointes. Am Heart J 122:1489 1492.
18. + currents in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 285:H661 H668.
19. Irwin JJ, Shoichet BK (2005). ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177 182.
20. IR2.1 channel expressed in a human cell line. J Physiol 556:61 78.
21. IR2.2 inward rectifier potassium channels. J Physiol 583:891 908.
22. IR2.1 breakdown directly influences inward rectifier current density. Biochem Biophys Res Commun 367:687 692.
23. Kannankeril PJ, Roden DM (2007). Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 22:39 43.
24. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA et al. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316 323.
25. Lai A Fat EJSK, Vrede MA, Soetosenojo RM, Lai A Fat RFM (2002). Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 41:796 800.
26. Lidman C, Bronner U, Gustafsson LL, Rombo L (1994). Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney. J Antimicrob Chemother 33:803 810.
27. Liew R, Stagg MA, MacLeod KT, Collins P (2004). Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the l-type calcium current. Br J Pharmacol 142:89 96.
28. Liu H, Jin MW, Xiang JZ, Huang Y, Sun HY, Chiu SW et al. (2007). Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Eur J Pharmacol 563:61 68.
29. Kr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 287:877 883.
30. + channels. Annu Rev Physiol 66:103 129.
31. Miake J, Marbán E, Nuss HB (2002). Biological pacemaker created by gene transfer. Nature 419:132 133.
32. Ming X, Ju W, Wu H, Tidwell RR, Hall JE, Thakker DR (2009). Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos 37:424 430.
33. Mitchell P, Dodek P, Lawson L, Kiess M, Russell J (1989). Torsades de pointes during intravenous pentamidine isethionate therapy. Can Med Assoc J 140:173 174.
34. Murphy CA, Dargie HJ (2007). Drug-induced cardiovascular disorders. Drug Saf 30:783 804.
35. Nagase S, Fukushima Kusano K, Yoshida M, Ohe T (2007). Electrophysiologic characteristics of an Andersen syndrome patient with KCNJ2 mutation. Heart Rhythm 4:512 515.
36. IR3.1 show sites for modulating gating and rectification. Nat Neurosci 8:279 287.
37. IR2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105:511 519.
38. 2-channel interactions. J Pharmacol Exp Ther 331:563 573.
39. Quadrel MA, Atkin SH, Jaker MA (1992). Delayed cardiotoxicity during treatment with intravenous pentamidine: two case reports and a review of the literature. Am Heart J 123:1377 1379.
40. Roden DM (1998). Taking the 'idio' out of 'idiosyncratic': predicting Torsades des Pointes. Pacing Clin Electrophysiol 21:1029 1034.
41. IR2.1 channel. Proc Natl Acad Sci USA 105:1364 1368.
42. Roza O, Berman LB (1971). The pathophysiology of barium: hypokalemic and cardiovascular effects. J Pharmacol Exp Ther 177:433 439.
43. Sands M, Kron MA, Brown RB (1985). Pentamidine: a review. Rev Infect Dis 7:625 633.
44. IR2.1 channel revealed by multiscale modeling. Biochemistry 48:8758 8763.
45. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A et al. (2002). Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 110:381 388.
46. Waalkes TP, Denham BA, DeVita VT (1970). Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol 11:505 512.
47. Waldman RH, Pearce DE, Martin RA (1973). Pentamidine isothionate levels in lungs, livers, and kidneys of rats after aerosol or intramuscular administration. Am Rev Respir Dis 108:1004 1006.
48. Werbovetz K (2006). Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 7:147 157.
49. White NJ (2007). Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7:549 558.
50. IR2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 332:1012 1019.
51. Yokoyama H, Nakamura Y, Iwasaki H, Hoshiai K, Mitsumori Y, Sugiyama A (2009). Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs. J Pharmacol Sci 110:476 482.
52. Zeegelaar JE, Steketee WH, Van Thiel PPAM, Wetsteyn JCFM, Kager FA, Faber WR (2005). Changing pattern of imported cutaneous leishmaniasis in the Netherlands. Clin Exp Dermatol 30:1 5.
53. Zhang L, Benson DW, Tristani-Firouzi M, Ptácek LJ, Tawil R, Schwartz PJ et al. (2005a). Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutation. Characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 111:2720 2726.
54. K1 in action potential shortening associated with atrial fibrillation in humans. Cardiovasc Res 66:493 502.